AUS
NZ
UK
CA
USA
IND
In the expansive landscape of the ASX 200, analysts have identified two standout ASX blue-chip stocks that present compelling investment opportunities. Coles Group Ltd (ASX:COL), the supermarket giant, and ResMed Inc (ASX:RMD), a prominent player in sleep treatment, have garnered bullish sentiments from experts. The rationale behind these endorsements reflects unique strengths and strategic initiatives that position these stocks favorably for investors. Let's delve into why analysts are particularly optimistic about Coles and ResMed in the current market scenario.
Coles Group Ltd (ASX: COL):
Coles Group, a retail behemoth renowned for its eponymous brand, emerges as a top blue-chip pick according to analysts, particularly those at Citi. The optimism stems from the company's proactive rollout of anti-theft technology, anticipated to significantly enhance its margins. Citi's bullish stance is encapsulated in their statement:
"The accelerated technology rollout should meaningfully lower the theft rate in 2H24. We expect the drag from theft on gross margin will begin to materially reverse in 2H24. Coles is rolling out technology to combat theft in ~30% of the store portfolio. Our analysis of retail theft data suggests that this should address ~70% of its theft exposure given that it will be rolled out to the most impacted stores initially. We forecast a 40 bps recovery in the supermarkets GP margin in 2H24e given these measures. We retain our Buy rating."
Citi maintains a Buy rating with a $17.50 price target on Coles Group shares.
ResMed Inc (ASX: RMD):
ResMed Inc, a leading player in sleep treatment, stands out as another blue-chip ASX 200 stock endorsed by analysts, notably at Morgans. Despite the emergence of weight loss drugs capturing market attention, Morgans dismisses concerns, asserting that these products will have minimal impact on the substantial and underserved sleep disorder breathing market. Morgans explains their positive outlook:
"While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain."
Morgans maintains an Add rating with a $32.74 price target on ResMed Inc shares.
Conclusion:
These endorsements highlight the strategic initiatives and unique strengths that make Coles Group and ResMed Inc stand out in the ASX 200 universe. Analysts' optimism reflects confidence in the companies' ability to navigate market challenges and capitalize on growth opportunities, making them noteworthy considerations for investors seeking blue-chip investments.
